Indivior Pharmaceuticals, Inc. (INDV) · Oct 6, 2026 · Acquisition

Indivior merger proxy amended after Supernus stockholder suits

Merger disclosure supplement — Two stockholder complaints and demand letters; October 15 special meetings remain scheduled

Indivior’s merger filing adds proxy disclosures after two Supernus stockholder complaints, but leaves the deal terms and October 15 votes unchanged.

Indivior is trying to accelerate SUBLOCADE-led growth in opioid-use-disorder treatment, while Supernus brings a broader neurology and psychiatry portfolio; the proposed combination is meant to create a more diversified CNS drug company.

The filing adds process risk, not a new transaction: After the definitive proxy was mailed, Supernus received stockholder demand letters and two New York complaints alleging incomplete merger disclosures. The companies deny the claims but are adding disclosures to reduce the chance of litigation delaying the deal. 〔0〕

The deal economics are not being renegotiated: The supplement corrects and expands banker-analysis inputs, including Supernus cash of approximately $372 million, Indivior cash of approximately $249 million, Indivior debt of approximately $500 million, and the $1 billion special dividend.

Deal-analysis itemUpdated disclosure
Supernus estimated cash~$372 million (Cantor analysis)
Supernus estimated debt$0 (Cantor analysis)
Indivior estimated cash~$249 million (Cantor analysis)
Indivior estimated debt~$500 million (Cantor analysis)
Special dividend$1 billion (Cantor analysis)
Supernus implied value range$50.55–$59.50 per share (Cantor analysis)
Indivior dividend-adjusted implied value range$24.20–$43.90 per share (Cantor analysis)

The immediate milestone is still the shareholder vote: Both companies are scheduled to hold special meetings on October 15, 2026. 〔1〕 The filing does not announce a changed exchange ratio, a revised closing date, or a new deal term; it mainly makes the proxy record more complete while litigation risk remains an added complication.

Bottom line: This is a procedural merger update with a modest negative wrinkle: stockholder litigation creates delay risk, but the transaction’s basic economics and voting timetable remain intact. The direction was already known; the new information is the disclosure dispute and corrected valuation inputs.

What to watch next

Indivior and Supernus stockholder votes, October 15

Original filing on SEC EDGAR

More Indivior Pharmaceuticals, Inc. news

Indivior merger proxy amended after Supernus stockholder suits | INDV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.